How A Rs 276 Stock Turned Into A Rs 20,000 Multibagger — Do You Own?
Neuland Laboratories is in focus in a quarterly results development.
· NDTV Profit
A Rs 1 lakh investment in Neuland Laboratories at Rs 276 per share would be worth around Rs 72.5 lakh at Rs 20,000, excluding dividends, taxes, and transaction costs. The pharma company’s earnings growth and changing business profile help explain its multibagger journey.
The analysis
Neuland Laboratories reported Rs 276, Rs 20,000 and Rs 1 lakh. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -2.6% on the day at ₹20,350.00, and has returned +6.2% over three months. It sits 15% below its 52-week high. The pharma & healthcare sector has moved -2.4% over the same period, so Neuland Laboratories is running 8.6 points ahead of its peers.
For Neuland Laboratories, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- The company directly in focus is NEULANDLAB.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads positive.
In this story
Related coverage
Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watch
BT BIG STORY: India Inc is more confident about Q3, but unwilling to hire or invest
Q2 Results Live: Tata Elxsi Rises 3% Ahead Of Earnings; ICICI Prudential Life Insurance, Anand Rathi Among Stocks In Focus
SMIDs rally heats up bets in IPO & secondary market; raises bar on earnings
ICICI Prudential Life Insurance to focus on growing absolute VNB amid slump in FY24